Search
Sinovac Pharmaceutical Initiates Phase II Clinical Trial of GB08 Injection with First Subject Enrolled
2025-09-02 /
Read about 0 minute
Author：小编
Shenzhen Sinovac Pharmaceutical, a wholly-owned subsidiary of Sinovac Pharmaceutical, proudly announces the successful enrollment and dosing of the first subject in the Phase II clinical trial of its proprietary Class I innovative drug, GB08 Injection. GB08, an Fc fusion protein long-acting growth hormone specifically designed to address pediatric growth hormone deficiency, marks Sinovac's pioneering effort in developing a Class I innovative drug.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
